DDX43
| DEAD (Asp-Glu-Ala-Asp) box polypeptide 43 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||||||
| Symbols | DDX43 ; CT13; HAGE | ||||||||||||
| External IDs | OMIM: 606286 HomoloGene: 56814 GeneCards: DDX43 Gene | ||||||||||||
| EC number | 3.6.4.13 | ||||||||||||
| |||||||||||||
| RNA expression pattern | |||||||||||||
 | |||||||||||||
| More reference expression data | |||||||||||||
| Orthologs | |||||||||||||
| Species | Human | Mouse | |||||||||||
| Entrez | 55510 | 100048658 | |||||||||||
| Ensembl | ENSG00000080007 | ENSMUSG00000070291 | |||||||||||
| UniProt | Q9NXZ2 | D3YVE3 | |||||||||||
| RefSeq (mRNA) | NM_018665 | NM_001191044 | |||||||||||
| RefSeq (protein) | NP_061135 | NP_001177973 | |||||||||||
| Location (UCSC) | Chr 6: 74.1 – 74.13 Mb | Chr 9: 78.4 – 78.42 Mb | |||||||||||
| PubMed search | |||||||||||||
Probable ATP-dependent RNA helicase DDX43 is an enzyme that in humans is encoded by the DDX43 gene.[1][2]
Function
The protein encoded by this gene is an ATP-dependent RNA helicase in the DEAD box family and displays tumor-specific expression.[2]
References
- ↑ Martelange V, De Smet C, De Plaen E, Lurquin C, Boon T (Aug 2000). "Identification on a human sarcoma of two new genes with tumor-specific expression". Cancer Res 60 (14): 3848–55. PMID 10919659.
- ↑ 2.0 2.1 "Entrez Gene: DDX43 DEAD (Asp-Glu-Ala-Asp) box polypeptide 43".
Further reading
- Hartley JL, Temple GF, Brasch MA (2001). "DNA cloning using in vitro site-specific recombination". Genome Res. 10 (11): 1788–95. doi:10.1101/gr.143000. PMC 310948. PMID 11076863.
- Wiemann S, Weil B, Wellenreuther R, Gassenhuber J, Glassl S, Ansorge W et al. (2001). "Toward a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs". Genome Res. 11 (3): 422–35. doi:10.1101/gr.GR1547R. PMC 311072. PMID 11230166.
- Simpson JC, Wellenreuther R, Poustka A, Pepperkok R, Wiemann S (2001). "Systematic subcellular localization of novel proteins identified by large-scale cDNA sequencing". EMBO Rep. 1 (3): 287–92. doi:10.1093/embo-reports/kvd058. PMC 1083732. PMID 11256614.
- Nagel H, Laskawi R, Eiffert H, Schlott T (2003). "Analysis of the tumour suppressor genes, FHIT and WT-1, and the tumour rejection genes, BAGE, GAGE-1/2, HAGE, MAGE-1, and MAGE-3, in benign and malignant neoplasms of the salivary glands". MP, Mol. Pathol. 56 (4): 226–31. doi:10.1136/mp.56.4.226. PMC 1187325. PMID 12890744.
- Wiemann S, Arlt D, Huber W, Wellenreuther R, Schleeger S, Mehrle A et al. (2004). "From ORFeome to biology: a functional genomics pipeline". Genome Res. 14 (10B): 2136–44. doi:10.1101/gr.2576704. PMC 528930. PMID 15489336.
- Mehrle A, Rosenfelder H, Schupp I, del Val C, Arlt D, Hahne F et al. (2006). "The LIFEdb database in 2006". Nucleic Acids Res. 34 (Database issue): D415–8. doi:10.1093/nar/gkj139. PMC 1347501. PMID 16381901.
- Mathieu MG, Knights AJ, Pawelec G, Riley CL, Wernet D, Lemonnier FA et al. (2007). "HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides". Cancer Immunol. Immunother. 56 (12): 1885–95. doi:10.1007/s00262-007-0331-2. PMID 17487488.